Editorial Material
Hematology
Nancy L. Bartlett
Summary: The study discusses a 10-year follow-up of a Children's Oncology Group trial for intermediate-risk Hodgkin lymphoma, highlighting the challenging task of optimizing treatment for this disease.
Article
Oncology
Matthew W. Parsons, Calvin Rock, Jonathan J. Chipman, Harsh R. Shah, Boyu Hu, Deborah M. Stephens, Randa Tao, Jonathan D. Tward, David K. Gaffney
Summary: Non-Hodgkin lymphoma survivors have an increased risk of secondary malignancies, with chemotherapy being associated with higher risk and radiotherapy not increasing overall risk. The risk of secondary malignancies varies among different racial groups and treatment modalities.
Article
Dermatology
A. Goyal, D. O'Leary, K. Goyal, N. Rubin, M. Janakiram
Summary: Patients with mycosis fungoides (MF) have an increased risk of developing various types of cancers, with those developing non-Hodgkin lymphoma (NHL), lung cancer, and bladder cancer tending to be diagnosed at earlier stages and showing better 5-year overall survival. Regular pigmented-lesion-focused skin examinations are recommended for MF patients, along with smoking cessation counseling and ensuring up-to-date cancer screenings. Regular imaging and lab testing for second malignancy screening require further study and expert consensus.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2021)
Article
Obstetrics & Gynecology
Francesco Pallotti, Marianna Pelloni, Fabiana Faja, Silvia Di Chiano, Alice Di Rocco, Andrea Lenzi, Francesco Lombardo, Donatella Paoli
Summary: Most NHL patients have normal sperm quality before treatment, but salvage therapy followed by stem cell transplant can cause permanent damage to sperm production, resulting in 66% of long-term azoospermic patients.
HUMAN REPRODUCTION
(2021)
Article
Oncology
Inge M. Krul, Naomi B. Boekel, Iris Kramer, Cecile P. M. Janus, Augustinus D. G. Krol, Marten R. Nijziel, Josee M. Zijlstra, Richard W. M. van der Maazen, Judith M. Roesink, Judy N. Jacobse, Michael Schaapveld, Marjanka K. Schmidt, Annemieke W. J. Opstal-van Winden, Gabe S. Sonke, Nicola S. Russell, Berthe M. P. Aleman, Flora E. van Leeuwen
Summary: Breast cancer patients after Hodgkin lymphoma (BC-HL) have limited treatment options due to prior HL treatment and increased risk of cardiovascular disease (CVD). BC-HL patients have worse BC outcomes and higher burden of CVD compared to BC-1 patients. Clinicians need to consider the increased CVD risk when selecting BC treatment for HL survivors.
Article
Oncology
Virginie Nerich, Christophe Guyeux, Michel Henry-Amar, Raphael Couturier, Catherine Thieblemont, Vincent Ribrag, Herve Tilly, Corinne Haioun, Rene-Olivier Casasnovas, Franck Morschhauser, Pierre Feugier, David Sibon, Loic Ysebaert, Emmanuelle Nicolas-Virelizier, Florence Broussais-Guillaumot, Gandhi L. Damaj, Jean-Philippe Jais, Gilles Salles, Macha Woronoff-Lemsi, Nicolas Mounier
Summary: This study focused on the health care resource use and associated costs in 1671 long-term NHL survivors in France. The results showed that most survivors utilized health care resources, with hospitalizations and outpatient treatments being major cost drivers. Several factors were found to have significant relationships with health care costs, but rituximab or autologous stem cell transplantation did not affect costs.
Article
Oncology
Zhenxing Lu, Yintong Teng, Xiaodong Ning, Hao Wang, Weijing Feng, Caiwen Ou
Summary: This study found that among patients with stage I and stage II classic Hodgkin lymphoma (cHL), the risk of cardiovascular disease (CVD) mortality exceeded that of cHL mortality over time, with CVD becoming the leading cause of death.
Article
Oncology
Aislinn Macklin-Doherty, Michael Jones, Penny Coulson, Cydney Bruce, Ian Chau, Emma Alexander, Sunil Iyengar, Mary Taj, David Cunningham, Anthony Swerdlow
Summary: The risk of thyroid disorders in females treated for Hodgkin lymphoma is related to the dose and area of radiotherapy, with no association with chemotherapy. The risk of thyroid disease is as high after adult as childhood treatment, and persists after recent treatment.
LEUKEMIA & LYMPHOMA
(2022)
Review
Medicine, General & Internal
Pauline Brice, Eric de Kerviler, Jonathan W. Friedberg
Summary: Classical Hodgkin lymphoma is a relatively common lymphoma that is generally considered highly curable with standard first-line chemotherapy and radiotherapy, although some patients may not be cured or may experience late toxic effects leading to premature death. Recent changes in the gold standard of chemotherapy, now often including immunotherapy in relapse settings, have further impacted treatment outcomes.
Article
Oncology
Elissa A. S. Polomski, Julius C. Heemelaar, Augustinus D. G. Krol, Marloes Louwerens, Saskia L. M. A. Beeres, Eduard R. Holman, J. Wouter Jukema, Martin J. Schalij, M. Louisa Antoni
Summary: This study demonstrates that LV dysfunction, including impaired GLS, in CHL survivors treated with thoracic radiotherapy is associated with cardiovascular events and cardiac death.
Review
Hematology
Zhumei Zhan, Wei Guo, Xin Wan, Ou Bai
Summary: With advancements in NHL therapeutics, long-term survival of NHL patients has increased. However, the concern for SPMs as a long-term complication for NHL survivors has grown. The factors leading to SPMs are multifactorial and include germline alterations, immune dysregulation, and external factors such as lifestyle and exposure to certain agents. Targeted therapies may reduce the incidence of t-MNs in indolent B-cell NHL.
ANNALS OF HEMATOLOGY
(2023)
Review
Oncology
Joaira Bakkach, Benedetta Pellegrino, Hagar Elghazawy, Olga Novosad, Sanjit Agrawal, Mohcine Bennani Mechita
Summary: Second breast cancer is the most common solid cancer among female survivors of Hodgkin Lymphoma, with risk factors including age at treatment, dose of radiation, and extent of irradiated field. These cancers tend to develop at a younger age, are often bilateral, and have aggressive biological features and poor prognosis. While literature does not firmly answer the benefits of breast surveillance, evidence leans towards clinical benefits of early detection.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Review
Obstetrics & Gynecology
Katja C. E. Drechsel, Maxime C. F. Pilon, Francis Stoutjesdijk, Salena Meivis, Linda J. Schoonmade, William Hamish B. Wallace, Eline van Dulmen-den Broeder, Auke Beishuizen, Gertjan J. L. Kaspers, Simone L. Broer, Margreet A. Veening
Summary: This narrative review summarized existing literature on reproductive function in young Hodgkin lymphoma survivors. The results showed that female survivors had a high incidence of premature ovarian insufficiency, while male survivors often experienced post-treatment azoospermia. Higher doses of chemotherapeutic agents and pelvic radiotherapy were associated with impaired reproductive ability.
HUMAN REPRODUCTION UPDATE
(2023)
Article
Hematology
Maja Dam Andersen, Stephen Hamilton-Dutoit, Lena Modvig, Maja Vase, Ilse Christiansen, Jacob Haaber Christensen, Rasmus Bo Dahl-Sorensen, Danny Stoltenberg, Peter Kamper, Francesco d'Amore
Summary: We analysed a large cohort of Hodgkin lymphoma patients to determine the pattern of late recurrence, the influential factors, and the outcome for patients experiencing recurrence.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Oncology
Danbee Kang, Sang Eun Yoon, Dongwook Shin, Jin Lee, Yun Soo Hong, Se Kyung Lee, Jeong Eon Lee, Yeon Hee Park, Jin Seok Ahn, Eliseo Guallar, Won Seog Kim, Jungho Lee, Seok Jin Kim, Juhee Cho
Summary: Research suggests that women with breast cancer have a higher risk of developing NHL, especially in younger age groups and those receiving hormone therapy.
BLOOD CANCER JOURNAL
(2021)
Article
Oncology
Mark N. Stein, Yu-Hui Chen, Michael A. Carducci, Gary R. Hudes, Pauline M. Lerma, Winston W. Tan, Robert Dalune, Kendrith M. Rowland, Timothy M. Kuzel, Robert S. DiPaola
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
(2019)
Article
Oncology
Laura E. G. Warren, Yu-Hui Chen, Lia M. Halasz, Jane E. Brock, Alexander Capuco, Rinaa S. Punglia, Julia S. Wong, Mehra Golshan, Jennifer R. Bellon
BREAST CANCER RESEARCH AND TREATMENT
(2019)
Article
Oncology
Jason W. D. Hearn, Christopher J. Sweeney, Nima Almassi, Chad A. Reichard, Chandana A. Reddy, Hong Li, Brian Hobbs, David F. Jarrard, Yu-Hui Chen, Robert Dreicer, Jorge A. Garcia, Michael A. Carducci, Robert S. DiPaola, Nima Sharifi
Article
Oncology
Umair Mahmood, Andrew Bang, Yu-Hui Chen, Raymond H. Mak, Jochen H. Lorch, Glenn J. Hanna, Mizuki Nishino, Claire Manuszak, Emily M. Thrash, Mariano Severgnini, Matthew Sanborn, Vishwajith Sridharan, Danielle N. Margalit, Roy B. Tishler, Paul M. Busse, Henning Willers, Harvey J. Mamon, Hyung-Jin Yoo, Sara Pai, Lori J. Wirth, Robert Haddad, Nicole G. Chau, Jonathan D. Schoenfeld
Summary: This study evaluated the safety and efficacy of pembrolizumab with or without radiation therapy in patients with adenoid cystic carcinoma. While no objective responses were observed, a majority of patients achieved stable disease with decreased tumor growth rate and half experienced clinical benefit exceeding 6 months. Favorable local responses were also observed within the radiation field, highlighting the need for additional strategies to delay progression and improve response.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Oncology
Richard Thomas, Yu-Hui Chen, Hiroto Hatabu, Raymond H. Mak, Mizuki Nishino
Article
Otorhinolaryngology
Mona Arbab, Yu-Hui Chen, Shana Criscitiello, Jason Glass, Jo Ann Fugazzotto, Joseph H. Killoran, Glenn Hanna, Jochen Lorch, Robert Haddad, Danielle N. Margalit, Roy B. Tishler, Jonathan D. Schoenfeld
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
(2020)
Article
Oncology
Jonathan D. Schoenfeld, Glenn J. Hanna, Vickie Y. Jo, Bhupendra Rawal, Yu-Hui Chen, Paul S. Catalano, Ana Lako, Zoe Ciantra, Jason L. Weirather, Shana Criscitiello, Adrienne Luoma, Nicole Chau, Jochen Lorch, Jason I. Kass, Donald Annino, Laura Goguen, Anupam Desai, Brendan Ross, Hina J. Shah, Heather A. Jacene, Danielle N. Margalit, Roy B. Tishler, Kai W. Wucherpfennig, Scott J. Rodig, Ravindra Uppaluri, Robert I. Haddad
Article
Hematology
Shing Fung Lee, Miguel Angel Luque-Fernandez, Yu Hui Chen, Paul J. Catalano, Chi Leung Chiang, Eric Yuk-Fai Wan, Ian Chi-Kei Wong, Ming Hui Chen, Andrea K. Ng
Article
Oncology
Jennifer R. Bellon, Yu-Hui Chen, Rebecca Rees, Alphonse G. Taghian, Julia S. Wong, Rinaa S. Punglia, Ron Y. Shiloh, Laura E. G. Warren, Monica S. Krishnan, John Phillips, Jennifer Pretz, Rachel Jimenez, Stephanie Macausland, Itai Pashtan, Chelsea Andrews, Steven J. Isakoff, Eric P. Winer, Sara M. Tolaney
Summary: The study aimed to evaluate the safety of cisplatin with radiation therapy in patients with early-stage TNBC, determining the maximum tolerated dose and recommending appropriate doses for different surgical approaches.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Oncology
Divya Yerramilli, Yu-Hui Chen, Veena Venkatachalam, Gabriela M. Alban, Daniela L. Buscariollo, Teresa Cheng, Martin T. King, Jennifer L. Pretz, Andrea L. Russo, Larissa J. Lee
Summary: This study analyzed survival outcomes and sites of failure for patients with FIGO stage IIIC endometrioid endometrial cancer treated with pelvic radiation therapy (PRT) versus extended-field radiation therapy (EFRT). The study found that isolated para-aortic relapse outside the PRT field was uncommon and amenable to salvage therapy for patients with positive pelvic nodes.
PRACTICAL RADIATION ONCOLOGY
(2021)
Article
Oncology
A. A. Hamid, H-C Huang, V Wang, Y-H Chen, F. Feng, R. Den, G. Attard, E. M. Van Allen, P. T. Tran, D. E. Spratt, R. Dittamore, E. Davicioni, G. Liu, R. DiPaola, M. A. Carducci, C. J. Sweeney
Summary: The study demonstrates the utility of transcriptomic subtyping for prognostication and potential selection of patients for chemohormonal therapy in mHSPC, and provides proof of concept for biomarker-guided selection of established combination therapies in mHSPC.
ANNALS OF ONCOLOGY
(2021)
Article
Hematology
Kevin X. Liu, Nicolas Poux, Kee-Young Shin, Nicholas Moore, Yu-Hui Chen, Steven Margossian, Jennifer S. Whangbo, Christine N. Duncan, Leslie E. Lehmann, Karen J. Marcus
Summary: This study compared the incidence of pulmonary toxicity (PT) after different myeloablative conditioning regimens in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) for leukemia and myelodysplastic syndrome (MDS). The results showed no significant difference in the occurrence of PT between the total body irradiation (TBI)-based and busulfan-based conditioning groups. Age, preexisting pulmonary conditions, acute and chronic graft-versus-host disease (GVHD) were associated with higher-grade PT, and higher-grade PT was associated with worse overall survival (OS).
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Article
Oncology
Alan H. Bryce, Yu Hui Chen, Glenn Liu, Michael A. Carducci, David M. Jarrard, Jorge A. Garcia, Robert Dreicer, Maha Hussain, Mario Alfredo Eisenberger, Elizabeth R. Plimack, Nicholas J. Vogelzang, Robert S. DiPaola, Lauren Harshman, Christopher J. Sweeney
EUROPEAN UROLOGY ONCOLOGY
(2020)
Article
Oncology
Kevin X. Liu, Yu-Hui Chen, David Kozono, Raymond H. Mak, Patrick J. Boyle, Katherine A. Janeway, Elizabeth A. Mullen, Karen J. Marcus
ADVANCES IN RADIATION ONCOLOGY
(2020)
Article
Oncology
Devarati Mitra, Yu-Hui Chen, Richard Li, Gretchen Hermann, Katelyn Atkins, David Kozono, Elizabeth H. Baldini, Ayal Aizer, Ugonma Chukwueke, Raymond H. Mak
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY
(2019)